Trials / Unknown
UnknownNCT02588755
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection：A Randomized Controlled Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Eastern Hepatobiliary Surgery Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE+Tegafur | Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection. |
| PROCEDURE | TACE | TACE alone |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-10-28
- Last updated
- 2016-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02588755. Inclusion in this directory is not an endorsement.